Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today

  • For my initial rating of Quest Diagnostics (DGX), I'm calling it a buy. Forecasts point to continuing demand for diagnostic testing, while the company also grew its business via acquisitions and new solutions. Strong profit margins, proven cashflow and dividend growth, and investment-grade credit ratings from major agencies are additional upside factors.